Healthcare · Drug Manufacturers - Specialty & Generic
Made onAug 1, 2026
Price at call$517.71
6-month call Bull +9.1%
Target by Feb 2027$565.00
Great value below$470.00
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change+9.1% to $565.00
Predicted High$565.00at 6 months
Predicted Low$515.00at 1 month
Max Drawdown (predicted)-0.5%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 1, 2026 1:00 am
Bull
UTHR trends higher to
$565.00
(+9.1% from $517.71)
by Feb 2027.
dip-then-recover
ThesisUTHR trades at a modest discount to composite fair value ($587) with strong quality, low beta, and a fresh positive Lancet readout providing gentle tailwind. Absent a catalyst-heavy calendar, expect gradual mean-reversion toward fair value with sentiment softening as the moonshot narrative fades.
Invalidated ifA break below $470 attractive-value zone on adverse Tyvaso or pipeline news, or breach above $600 on M&A or surprise catalyst.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $517.71 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 1, 2026
—
$517.71at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Aug 15, 2026
$494.54–$540.88typical range · internal point $520.50
—
±4.5%
6/10
Low-beta drift, neutral regime, minor Lancet lift
What actually happened:
closed $499.73
on Aug 14, 2026 = -3.5% vs the call
(predicted +0.5%)
· direction HIT
(called flat, was flat)
· off by 4.0 pp
· accuracy 8/10
· typical range ±4.5%:
inside the band
· S&P +4.0%
over the same window — beat it
1 month
Sep 1, 2026
$484.13–$551.29typical range · internal point $515.00
—
±6.5%
5/10
Moonshot narrative fade offsets quality bid
What actually happened:
closed $512.70
on Sep 1, 2026 = -1.0% vs the call
(predicted -0.5%)
· direction HIT
(called flat, was flat)
· off by 0.4 pp
· accuracy 10/10
· typical range ±6.5%:
inside the band
· S&P +1.9%
over the same window — beat it
2 months
Oct 1, 2026
$525.00
—
+1.4%
5/10
Q3 print anticipation, beat streak supports
What actually happened:
closed $541.89
on Sep 30, 2026 = +4.7% vs the call
(predicted +1.4%)
· direction HIT
(called flat, was flat)
· off by 3.3 pp
· accuracy 9/10
· S&P +2.2%
over the same window — lagged it
3 months
Nov 1, 2026
$540.00
—
+4.3%
5/10
Earnings beat likely; value gravity engages
Matured — awaiting scoring. This checkpoint's date has passed; the next scorer run
(score-outcomes.php) records what actually happened.
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$564.47
(+9.0%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.
All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.
Value anchors (from deep analysis)
Price at call
$517.71
Composite fair value
$587.34
Signal-adjusted fair value
$650.49
DCF fair value
$543.76
Anchored-PE fair value
$930.76
Buy-below (value lens)
$470.00
Value net score
-9
Value confidence
6 / 10
Quality net score
+74
Memo confidence
7 / 10
Deserved value (base)
—
Quality tilt
—
Deserved value (used)
—
Coherence (value × quality)
—
Price behaviour (trailing — shapes the realism line)